Why is Beryl Drugs falling/rising?

As of 19-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 22.61, reflecting a decrease of 0.96, or 4.07%. The stock has underperformed its sector today by 4.34%, and its delivery volume has fallen by 8.23% compared to the 5-day average, indicating a decrease in investor participation. Over the past week, the stock has seen a significant drop of 6.95%, while its year-to-date return stands at a troubling -37.46%. Despite a relatively attractive valuation with a return on capital employed (ROCE) of 11, the stock's profits have decreased by 37% over the past year, contributing to its negative performance. The company has also shown weak long-term growth, with net sales and operating profit growing at rates of only 12.86% and 13.21%, respectively, over the last five years.
In the broader market context, Beryl Drugs has underperformed significantly compared to the Sensex, which has gained 0.88% over the past week. The stock's performance over the last year is particularly concerning, as it has fallen by 36.33% while the broader market (BSE500) has only declined by 1.96%. This stark contrast highlights the company's struggles in maintaining investor confidence and servicing its debt, as indicated by a poor EBIT to interest ratio of 0.86. Overall, the combination of weak fundamentals, declining investor interest, and significant underperformance relative to the market has led to the stock's current downward trajectory.